CSI Market
Sign In | Register

Vaxcyte Inc (PCVX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PCVX quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Vaxcyte Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-766.63
Depreciation & amortization16.40
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation138.85
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities-
Increase Decrease In Accrued Compensation2.30
Increase Decrease In Accrued Manufacturing Expenses31.06
Increase Decrease In Accrued Legal Settlement-
Operating Lease Right Of Use Asset Amortization Expense8.46
Non Cash Payments For Acquire Manufacturing Rights-
Foreign Currency Transaction Gain Loss Unrealized After Tax-34.77
Increase Decrease In Operating Lease Right Of Use Assets-
Increase Decrease In Operating Lease Right Of Use Asset-52.37
Increase Decrease In Operating Lease Liability46.37
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable19.91
Increase (Decrease) in Accrued Liabilities5.97
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-16.80
Other Working Capital-39.89
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-14.43
Discontinued operations0.00
Net Cash flow from Operating Activities-655.58
Investing Activities
Capital Expenditures-13.71
Sale of Capital Items0.00
Short-term Investments Proceeds1,705.83
Payments to Acquire Available-for-sale Securities, Debt1,211.50
Real Estate Investments0.00
Payment For Equipment Manufacturing Facility Construction In Progress-
Payments To Acquire Manufacturing Facility And Equipment-43.26
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-2,423.00
Discontinued operations0.00
Net Cash Flow from Investing Activities437.35
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock13.01
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-400.19
Payments Of Capital Lease Obligations-
Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options-
Payment Of Deferred Offering Costs-
Proceeds From Issuance Of Common Stock Under The Employee Stock Purchase Plan-
Proceeds From Follow On Public Offering Net Of Underwriters Commissions And Discounts-
Proceeds From Issuance Of Common Stock From Follow On Offering Net Of Issuance Costs-
Release Of Restricted Stock Units Value-
Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Follow On Offerings Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents389.20
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities2.01
Effect of exchange rate on cash flow2.44
Discontinued operations0.00
Free Cash Flow-669.29
Total Cash Flow-213.77
4 historic quarters locked

Sign in to unlock the full Vaxcyte Inc cash flow history.

Sign In Create Free Account

About Vaxcyte Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 24, 2026
  • Source: pcvx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001649094-26-000007

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License